Is Arcutis Biotherapeutics Inc (ARQT) overvalued? · rev $196.5M
Arcutis Biotherapeutics Inc (ARQT) is a biotechnology company listed on US.
This page asks whether Arcutis Biotherapeutics Inc (ARQT) looks expensive on cached numbers — not a short thesis.
Latest reported ARQT revenue for 2024-12-31 was $196.5M. Net income was -$140.0M. Revenue was up 229.7% from 2023-12-31 to 2024-12-31. ARQT currently screens at market cap $1.64B.
ARQT currently screens at market cap $1.64B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ARQT 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ARQT stock page for the full model, not this heading.
Not investment advice.